Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care June 2003	HMO, Medicaid formularies exhibit surprisingly small differences When you compare HMO and Medicaid formularies for coverage in major therapeutic areas, you find that the differences are relatively small, with Medicaid plans being somewhat less stringent.
Managed Care November 2002	Flu season: Most HMO formularies cover Tamiflu, Relenza As the influenza season approaches, managed care patient access to Tamiflu (oseltamivir) from Roche Laboratories and Relenza (zanamivir) from GlaxoSmithKline, the two medications indicated for influenza, looks relatively open.
Managed Care March 2005	ED drugs covered, but managed care unmoved Health care insurers account for the coverage of erectile dysfunction drugs.
Managed Care November 2004 Tony Berberabe	Military Brings Order To Formulary System Congress told the Department of Defense to create a uniform formulary for all the services, and cover all FDA-approved drugs.
Managed Care October 2005 Martin Sipkoff	Restrictive Formularies May Be Contagious It's the law of unintended consequences: A restrictive drug formulary maintained by a health plan may influence how physicians treat patients unaffiliated with that plan. What does this mean to managed care?
Managed Care May 2001	Old Ideas About Formulary Structure Gone as Humana Tests 4-Tier Model Humana is phasing in a four-tier formulary that categorizes prescription drugs by costs, rather than generic or brand status. The higher the drug's acquisition cost -- regardless of whether it's a branded or generic product -- the higher the tier it lands in...
Pharmaceutical Executive May 1, 2011 Mason Tenaglia	Out of Control The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
Managed Care February 2002 Bob Carlson	Proposal To Regulate Formularies Draws Sharp Difference of Opinion The National Association of Insurance Commissioners has spent two years developing a model. Drug companies like it; health plans don't...
The Motley Fool November 18, 2004 Lawrence Meyers	Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction.
Managed Care December 2000	AMCP To Test New Guidelines For Formularies The Academy of Managed Care Pharmacy thinks there's a better way for health plans and pharmacy benefit managers to make formulary decisions than by simply looking at line-item budget figures...
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
Managed Care October 2004 Tony Schueth	Formulary Standards Key To E-Prescribing Success Electronic prescribing needs standardization before it's adopted by the masses. Start with the format of formulary databases.
Managed Care March 2000 Tim Sawyers	Test Prospective PBM Before Signing Contract How to select, then monitor a pharmacy benefit management company, from a consultant and former HMO director of pharmacy services.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
Pharmaceutical Executive March 1, 2007 George Koroneos	Marketing to Professionals: The Formulary Rebound Marketers' professional strategies often fall on deaf ears when there is a cheap alternative available. Here are some tactics that make your brand heard.
Managed Care July 2001 Bob Carlson	Oregon Attempts To Blaze Trail With 'Reference-Based' Formulary Pharmaceutical makers invest enormous sums in R&D -- but they also reap enormous profits. States are impatient with the appearance that creates...
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
Managed Care March 2001	Single-source drugs get formulary preference Managed care organizations often place costly new drugs on a formulary's priciest tier, but products for which substitutes do not exist often are made available at lower copayment levels...
BusinessWeek December 13, 2004 Carol Marie Cropper	The Inside Dope on Drugs Watchdog Web sites can tip you off to concerns that may not be on the label. Still, before you hit the Net, start with your doctor. And don't overlook the FDA's home page.
Managed Care August 2005	Dronabinol Can't Replace Medical Marijuana Controversy regarding Marinol revolves around it's synthesized, single compound and the time it tales to become effective.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
Pharmaceutical Executive March 3, 2014 Mason Tenaglia	The New Metrics of Market Success Profitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?
Managed Care August 2001 Steve Perlstein	Four-Tier Approach Injects Consumerism Into Drug Benefit In tying copayments closely to the actual cost of medications, Humana takes a step toward promoting awareness of resource use...
The Motley Fool April 11, 2007 Billy Fisher	A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders.
Managed Care February 2001 T. Jeffrey White	Making Pharmacoeconomics In Formulary Development a Reality Despite what might be commonly believed, pharmacoeconomics is not a widely used tool for formulary development. Here's a model to follow...
The Motley Fool December 28, 2004 W.D. Crotty	Pfizer: For Value Eyes Only While clearly not for conservative investors, this pharmaceutical deserves the attention of those looking for a value play.
The Motley Fool April 7, 2011 Brian Orelli	When Zombies Attack, Investors Win Novartis is hoping that Prexige has as much success coming back from the dead as Tysabri has.
Managed Care December 2003	Electronic prescribing has no effect on formulary compliance A retrospective analysis of claims data from Aetna indicates that systems that allow physicians to enter prescriptions electronically on a handheld device that also provides drug information and formulary status have no significant effect on compliance with formularies and utilization of generics.
Managed Care November 2004 John Carroll	Medicare Formulary Model Seen by Many as Too Inclusive The issue is how extensive the list of covered medications should be for the new Medicare pharmaceutical benefit. The stakes are enormous.
Managed Care February 2007 MargaretAnn Cross	How Much Trouble Does Health Care Marketing Cause? Whether for drugs, imaging, surgery, or emergency services, direct-to-consumer advertising sparks lively debate.
Managed Care December 2002	California Puts Doctor Scores On Report Cards The competency of physician groups is often as important as HMO performance in determining patient outcomes, California health regulators have decided
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
Managed Care July 2001	Compensating the pharmacy services manager One of the positions that Warren Surveys looked at when it tracked the salaries of 266 titles at over 500 HMO and managed care companies was pharmacy services manager...
Managed Care September 1999	Headlines on Deadline... Healthcare industry news briefs.
Pharmaceutical Executive February 1, 2014 Jill Wechsler	Drug Coverage, Costs Under Scrutiny Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies
Managed Care July 2002 Thomas Kaye	Managing the Drug Benefit: One Company's Experience The pharmacy director of Blue Cross of Oklahoma shares his company's success with using three tiers and coinsurance to promote member responsibility.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
Managed Care June 2002	Report: Physicians storm Web sites to get information on formularies A study shows a big increase over the course of a year in the number of physician hits on HMO sites to get information on claims status, clinical guidelines, and many other topics.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
Managed Care November 2002 MargaretAnn Cross	Formulary Submission Process Catches On ... Slowly If drug purchasers are so bullish on what the Academy of Managed Care Pharmacy's Format for Formulary Submissions can do for them, why don't more of them use it?
Managed Care February 2002 Joyce Ochs	E-Prescribing Gets More Enticing Physicians today are writing prescriptions for patients on palm-held devices that seem eerily akin to medical practice on the Starship Enterprise...
Managed Care December 2006	The Formulary Files Four core strategies are used to manage outpatient specialty pharmacy costs.
Managed Care December 2002	Generic Prilosec... Ready or not, here it comes A consortium of manufacturers has received FDA approval to launch a generic version of the huge-selling proton-pump inhibitor Prilosec (omeprazole). The launch is expected by the end of the year. How will MCO drug formularies react? Watch this space.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
InsideFlyer December 2011	BA Executive Club Elite British Airways Executive Club is making changes to its elite program, including adding a new elite tier.
Managed Care June 2005 Martin Sipkoff	MMA Formulary Design Requires Health Plans To Control Costs Despite a mandate to adopt utilization management programs and make patients share costs, health plans are still lining up to participate in Medicare Part D.
Managed Care January 2001	Express Scripts' Formulary Rulings To Go Online The public will have a chance to see what until now has been, mostly, understood only by managed care insiders: how a prescription drug winds up on a formulary...
Managed Care November 2006	The Formulary Files Step therapy for antidepressants saves 11.7 percent in one year.